Cargando…
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
SIMPLE SUMMARY: Minimal residual disease (MRD) represents a status of the disease which is assumed to still be present in the body until it is clinically observed by radiology. At this time point, the tumor relapse is present and a new clinical decision should be taken. However, there is currently n...
Autores principales: | Larribère, Lionel, Martens, Uwe M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616165/ https://www.ncbi.nlm.nih.gov/pubmed/34830853 http://dx.doi.org/10.3390/cancers13225698 |
Ejemplares similares
-
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022) -
Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021) -
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020) -
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Peng, Yan, et al.
Publicado: (2021) -
Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
por: Zhu, Lemei, et al.
Publicado: (2023)